RA CAPITAL MANAGEMENT, L.P.
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$9.97B2026 Q3
Positions92
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.61.3%
What Changed This Quarter?
Top Holdings
ASND
Ascendis Pharma A/S
23.5%
PBLS
Parabilis Medicines
9.5%
PCVX
Vaxcyte
6.5%
RYTM
Rhythm Pharmaceuticals
6.4%
EWTX
Edgewise Therapeutics
3.4%
TYRA
Tyra Biosciences
2.7%
FRNM
Freenome
2.4%
COAG
Hemab Therapeutics
2.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.